Skip to main content
. 2013 May 2;121(24):4917–4924. doi: 10.1182/blood-2013-03-493197

Table 1.

Clinical characteristics and patient outcome of study cohort

IDH wild-type (n = 161) IDH mutant (n = 62) P value IDH2 R140Q mutant (n = 26)
Median age, y (range) 46 (18-60) 46 (18-60) .89 47 (27-59)
Male/female ratio 80/81 (1:1) 26/36 (1:1.4) .37 13/13 (1:1)
Treatment group, n (%) .23
 DNR 45 mg/m2 83 (52) 26 (42) 8 (31)
 DNR 90 mg/m2 78 (48) 36 (58) 18 (69)
Median WBC count at dx (×109/L) 31.8 (0.6- 212.8) 34.7 (1.0-191.8) .62 44.0 (1.7-191.8)
Median PLT count at dx (×109/L) 67.2 (3.9- 452) 101.7 (6.2- 650) .002 94.3 (17-304)
Median BM blast % at dx (range) 61.2 (8- 99) 71.8 (22-100) .009 72.2 (25-100)
Median PB blast % at dx (range) 44.9 (0- 98) 48.4 (0-97) .49 55.8 (0-97)
Cytogenetic risk group, n (%) <.0005
 Favorable 0 (0) 1 (2) 0 (0)
 Intermediate 146 (91) 40 (65) 16 (62)
 Unfavorable 1 (1) 7 (11) 4 (15)
 Indeterminate 14 (9) 14 (23) 6 (23)
Mutations present, n (%)
FLT3-ITD 76 (48) 12 (20) <.0005 6 (23)
FLT3-TKD 12 (8) 2 (3) 2 (8)
NPM1 74 (47) 32 (53) .45 16 (62)
TET2 11 (7) 0 (0) .087 0 (0)
DNMT3A 44 (28) 20 (33) .022 4 (15)
CEBPA 20 (13) 1 (2) .023 0 (0)
Achieved CR, n (%) 103 (64) 40 (65) .824 19 (73)
Median survival duration (mo) 18.2 45.3 .022 Not reached

DNR, daunorubicin; dx, diagnosis; FLT3-ITD, FLT3 internal tandem duplication; FLT3-TKD, FLT3 tyrosine kinase domain; PLT, platelet

HHS Vulnerability Disclosure